FDA Brief

Warning letters Drugs

FDA warning letter to

Creative Essences, Inc.

High riskIssued Sep 25, 2025Posted Oct 7, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

What happened

FDA inspected the Santa Fe Springs, CA drug manufacturing facility from March 19 to 25, 2025, and reviewed the company’s April 15, 2025 response to the Form FDA 483 (inspection observations). It found significant current good manufacturing practice (CGMP) failures in investigations, laboratory controls and microbial testing, identity testing of components such as glycerin and propylene glycol, process validation and water-system control, and quality-unit oversight. FDA also said a redacted product is intended as a topical antiseptic but is an unapproved new drug and misbranded.

What FDA found

  1. The company did not thoroughly investigate out-of-specification results or other unexplained failures, find root causes, take effective corrective actions, or check whether other batches were affected.

    21 CFR 211.192
  2. The company lacked adequate finished-product sampling and testing and could not show its microbial test methods were suitable for their intended use.

    21 CFR 211.160(b)
  3. The company did not perform adequate identity testing on each incoming lot of components, including glycerin and propylene glycol, to screen for diethylene glycol (DEG) and ethylene glycol (EG), and did not establish the reliability of supplier certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The company lacked process validation data and did not adequately qualify, sanitize, or monitor its water system, which is used as a component and for cleaning.

    21 CFR 211.100(a)
  5. The quality unit did not ensure needed procedures, equipment cleaning and maintenance, or a stability testing program to set storage conditions and expiration dates.

    21 CFR 211.22; 211.22(d); 211.67(b); 211.166(a)
  6. A redacted product intended as a topical antiseptic is an unapproved new drug and misbranded because it lacks an FDA-approved application and does not meet the OTC monograph conditions.

    FD&C Act sections 505(a), 301(d), 502(ee), and 301(a)

What FDA wants

FDA tells the company to respond with comprehensive independent assessments and remediation plans for its investigation/CAPA, laboratory, component, validation/water, and quality-unit systems. It specifically requires DEG/EG test results no later than 30 calendar days from the letter and risk assessments plus customer notification or recall actions for within-expiry products at risk.

Who should pay attention

  • brands that use this contract manufacturer for OTC drugs
  • distributors or retailers selling the affected OTC products
  • quality teams handling glycerin and propylene glycol suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk